Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Patent
1996-02-28
2000-04-04
Mertz, Prema
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
514 2, 514 8, 514 12, 514885, 514886, 514887, 4241841, 4241981, A61K 3820
Patent
active
060457880
ABSTRACT:
A method of activating the immune system of a subject comprises the chronic administration of low doses of an agent such as IL-2, fusion proteins thereof and derivatives thereof that are pharmaceutically acceptable. The agent is provided as a dermal composition, transdermal delivery device and electrotransport device as well as in the form of a kit for self-administration.
REFERENCES:
patent: 4933433 (1990-06-01), Tamblyn
patent: 4938956 (1990-07-01), Howard et al.
patent: 4940456 (1990-07-01), Sibalis et al.
patent: 5126129 (1992-06-01), Wiltrout et al.
patent: 5229109 (1993-07-01), Grimm et al.
patent: 5420109 (1995-05-01), Suto et al.
Roland Mertelsmann et al., "Treatment of Immunodeficiency with Interleukin-2: Initial Exploration", Journal of Biological Response Modifiers, 4:483-490 (1984) Raven Press, NY.
H. Clifford Lane et al., "Use of Interleukin-2 in Patients with Acquired Immunodeficiency Syndrome", Journal of Biological Response Modifiers, 3:512-516, (1984), Raven Press, NY.
Steven A. Rosenberg et al., "Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin--2 to Patients with Metastatic Cancer", The New England Journal of Medicine, (Dec. 5, 1985), pp. 1485-1492.
Yang et al., (1995) Cancer,vol. 76, No. 4, pp. 687-694.
Paul Volberding et al., "Therapy of Acquired Immune Deficiency Syndrome with Recombinant Interleukin-2", Aids Research and Human Retroviruses, vol. 3, No. 2, (1987), pp. 115-124.
Michael A. Caliguiri et al., "Extended Continuous Infusion Low-Dose Recombinant Interleukin-2 in Advanced Cancer: Prolonged Immunomodulation Without Significant Toxicity", Journal of Clinical Oncology, vol. 9, No. 12, (Dec. 1991), pp. 2110-2119.
Michael A. Caligiuri et al., "Selective Modulation of Human Natural Killer Cells in Vivo After Prolonged Infusion of Low Dose Recombinant Interleukin 2", J. Clin. Invest., vol. 91, (Jan. 1993), pp. 123-132.
Gilla Kaplan et al., "The Reconstitution of Cell-Mediated Immunity in the Cutaneous Lesions of Lepromatous Leprosy by Recombinant Interleukin-2," J. Exp. Med., The Rockefeller University Press, vol. 169, (Mar. 1989), pp. 893-907.
David H. Schwartz et al., "Safety and Effects of Interleukin-2 Plus Zidovudine in Asymptomatic Individuals Infected with Human Immunodeficiency Virus," J. of Acquired Immune Deficiency Syndromes, vol. 4, No. 1, (1991) pp. 11-23.
Robert J. Soiffer, "Effect of Low-Dose Interleukine-2 on Disease Relapse After T-Cell-Depleted Allogeneic Bone Marrow Transplantation." Blood, vol. 84, No. 3, (1994), pp. 964-971.
Hedy Teppler et al., "Efficacy of Low Doses of the Polyethylene Glycol Derivative of Interleukine-2 in Modulating the Immune Response of Patients with Human Immunodeficiency Virus Type 1 Infection," The Journal of Infectious Diseases, (1993), 167, pp. 291-298.
Zale P. Bernstein et al., "Prolonged Administration of Low-Dose Interleukine-2 in Human Immunodeficiency Virus-Associated Malignancy Results in Selective Expansion of Innate Immune Effectors Without Significant Clinical Toxicity," Blood, vol. 86, No. 9, (1995) pp. 3287-3294.
Joseph A. Kovacs, M.D., "Increases in CD-4 Lymphocytes with Intermittent Courses of Interleukin-2 in Patients with Human Immunodeficiency Virus Infection," The New England Journal of Medicine, vol. 332, No. 9, (Mar. 2, 1995), pp. 567-575.
Concorde Coordinating Committee, "Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in sympton-free HIV infection," The Lancet, vol. 343 (1994), pp. 871-881.
Yang et al., (1995) Cancer, vol. 76. No. 4, pp. 687-694.
PCT International Search Report.
Morikawa, K. et al., "Enhancement of Therapeutic Effects of Recombinant Interleukin 2 on a Transplantable Rat Fibrosarcoma by the Use of a Sustained Release Vehicle, Pluronic Gel" Cancer Research 47: 37-41, 1987.
Yang et al. (1995) Cancer, vol. 76. No. 4, pp. 687-694.
Amzel Viviana
Cornell Research Foundation Inc.
Mertz Prema
LandOfFree
Method of stimulation of immune response with low doses of IL-2 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of stimulation of immune response with low doses of IL-2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of stimulation of immune response with low doses of IL-2 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-362159